Steven Cohen’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$345K Buy
47,783
+4,156
+10% +$36.2K ﹤0.01% 3284
2026
Q2
$455K Buy
+43,627
New +$323K ﹤0.01% 3214
2026
Q1
– Sell
-33,871
Closed -$244K – 4381
2025
Q4
$244K Buy
+33,871
New +$274K ﹤0.01% 3560
2020
Q4
– Sell
-13,333
Closed -$992K – 1100
2020
Q3
$992K Sell
13,333
-20,000
-60% -$1.53M 0.01% 779
2020
Q2
$2.84M Buy
33,333
+4,549
+16% +$412K 0.02% 552
2020
Q1
$2.08M Buy
+28,784
New +$2.78M 0.02% 500
2018
Q1
– Sell
-3,338
Closed -$982K – 1094
2017
Q4
$982K Buy
+3,338
New +$1.46M ﹤0.01% 804
2017
Q3
– Sell
-3,995
Closed -$2.38M – 1030
2017
Q2
$2.38M Buy
+3,995
New +$1.76M 0.01% 621

Other funds holding RNAC

Steven Cohen's RNAC Position: Q3 2026 in Review

Steven Cohen increased its Cartesian Therapeutics (RNAC) stake by 9.5% in Q3 2026, buying an estimated $36.2K and bringing the position to 47,783 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #3284.

Steven Cohen first reported a position in RNAC in Q2 2017 and has held it in 8 quarters since. The position peaked at $2.84M in Q2 2020. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Steven Cohen held 47,783 shares of Cartesian Therapeutics worth $345K as of Q3 2026.
  • Steven Cohen bought 4,156 Cartesian Therapeutics shares in Q3 2026, an estimated $36.2K.
  • Cartesian Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #3284 holding.
  • Steven Cohen first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 8 quarters since.
  • Steven Cohen's Cartesian Therapeutics position peaked at $2.84M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.